Home › NCT07281391
IOP Reduction in Pigmentary Glaucoma Using DSLT
RecruitingObservational study
Direct Selective Laser Trabeculoplasty Providing Effective Intraocular Pressure Reduction in Pigmentary Glaucoma Patients
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult patients with pigmentary dispersion syndrome with elevated IOP or mild to moderate (based on AAO Preferred Practice Program criteria) pigmentary glaucoma with glaucomatous optic neuropathy and corresponding visual field/RNFL loss. * Treatment naive, or washed out IOP ranging from ≥18-34 mmHg * Central corneal thickness (CCT) 480-600 µm * Able to complete medication washout and follow-up Exclusion Criteria: * Prior incisional glaucoma surgery or glaucoma-related procedures in the study eye * Prior laser trabeculoplasty \<3 years * Prior intraocular surgery and refractive surgery, except for cataract surgery unless greater than 2 years * Patients anticipating cataract surgery within the follow-up period * History of ocular inflammation and infection * All other secondary glaucoma including exfoliative * Patients unable to have DSLT treatment
About the study
This study is a single-site, single-arm, prospective, observational study of IOP reduction after DSLT. Subjects will be assessed up to 12 months post-operatively. Clinical evaluations will include IOP and number of glaucoma medications.
What is being tested
- Voyager DSLT (device)
Sponsor: Mann Eye Institute · Participants: 45 · Started: Mar 19, 2026
Contact the study team
- Melissa Wright · Phone: 713-580-2500
Official record on ClinicalTrials.gov — NCT07281391
Locations in the U.S.
| Texas | Mann Eye Institute, Houston |
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.